Sorin Group Signs Supply Agreement For Boston Scientific Lotus Valve System

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the signing of a supply agreement for the manufacturing of certain components of the Lotus Aortic Valve System, Boston Scientific Corporation’s second-generation TAVR (Transcatheter Aortic Valve Replacement) technology. Under the terms of this agreement, Sorin Group will perform certain manufacturing steps related to the tissue valve in its facility in Vancouver (Canada).

“This agreement recognizes the strong valve manufacturing experience that Sorin Group has accumulated across its European and North American operations,” said Michel Darnaud, President of Sorin Group, Cardiac Surgery Business Unit, “building on more than 40 years of innovation, development, clinical validation and commercialization in the field of mechanical and tissue prosthetic heart valves.”

The Lotus Aortic Valve System is an investigational device worldwide, limited by applicable law to investigational use and not available for sale.